

according to the OSHA Hazard Communication Standard

Sitagliptin / Ipragliflozin L-Proline Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.1	09/30/2023	3121447-00013	Date of first issue: 08/28/2018

SECTION 1. IDENTIFICATION

Product name	:	Sitagliptin / Ipragliflozin L-Proline Formulation			
Manufacturer or supplier's details					
Company name of supplier	:	Merck & Co., Inc			
Address	:	126 E. Lincoln Avenue			
		Rahway, New Jersey U.S.A. 07065			
Telephone	:	908-740-4000			
Emergency telephone	:	1-908-423-6000			
E-mail address	:	EHSDATASTEWARD@merck.com			
Recommended use of the chemical and restrictions on use					
Recommended use	:	Pharmaceutical			
Restrictions on use	:	Not applicable			

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR
1910.1200)

Combustible dust

Eye irritation	:	Category 2A
Reproductive toxicity	:	Category 2
Specific target organ toxicity - repeated exposure	:	Category 2 (Kidney, Liver)
GHS label elements Hazard pictograms	:	
Signal Word	:	Warning
Hazard Statements	:	If small particles are generated during further processing, han- dling or by other means, may form combustible dust concentra- tions in air. H319 Causes serious eye irritation. H361d Suspected of damaging the unborn child. H373 May cause damage to organs (Kidney, Liver) through prolonged or repeated exposure.
Precautionary Statements	:	Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust.

according to the OSHA Hazard Communication Standard



Sitagliptin / Ipragliflozin L-Proline Formulation

sion	Revision Date: 09/30/2023	SDS Number: 3121447-00013	Date of last issue: 04/04/2023 Date of first issue: 08/28/2018
			n thoroughly after handling. tective gloves, protective clothing, eye protectior tion.
		for several mine to do. Continue P308 + P313 IF	P338 IF IN EYES: Rinse cautiously with water utes. Remove contact lenses, if present and eas rinsing. exposed or concerned: Get medical attention. eye irritation persists: Get medical attention.
		Storage: P405 Store locl	ked up.
		Disposal:	
		P501 Dispose o disposal plant.	of contents and container to an approved waste
Othe	r hazards		
Conta	act with dust can caus	se mechanical irritation	or drying of the skin.

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 30 - < 50
Ipragliflozin L-proline	951382-34-6	>= 10 - < 20
Sitagliptin	654671-77-9	>= 10 - < 20
Magnesium stearate	557-04-0	>= 1 - < 5

Actual concentration is withheld as a trade secret

: Mixture

SECTION 4. FIRST AID MEASURES

Substance / Mixture

General advice	 In the case of accident or if you feel unwell, seek mean advice immediately. When symptoms persist or in all cases of doubt seek advice. 	
If inhaled	: If inhaled, remove to fresh air. Get medical attention.	
In case of skin contact	 In case of contact, immediately flush skin with soap a of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. 	nd plenty
In case of eye contact	 In case of contact, immediately flush eyes with plenty for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention. 	of water
If swallowed	: If swallowed, DO NOT induce vomiting.	



Version 3.1	Revision Date: 09/30/2023	SDS Number: 3121447-00013	Date of last issue: 04/04/2023 Date of first issue: 08/28/2018			
Most important symptoms and effects, both acute and delayed		 Get medical attention. Rinse mouth thoroughly with water. Causes serious eye irritation. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure. 				
Protection of first-aiders Notes to physician		the skin. : First Aid resp and use the r when the pote	 Contact with dust can cause mechanical irritation or drying or the skin. First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). Treat symptomatically and supportively. 			

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides Metal oxides
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).



Version 3.1	Revision Date: 09/30/2023	SDS Number: 3121447-00013	Date of last issue: 04/04/2023 Date of first issue: 08/28/2018
		surfaces, as the released into th Local or nationa disposal of this employed in the determine whic Sections 13 and	hould not be allowed to accumulate on ese may form an explosive mixture if they are e atmosphere in sufficient concentration. al regulations may apply to releases and material, as well as those materials and items e cleanup of releases. You will need to h regulations are applicable. d 15 of this SDS provide information regarding national requirements.
SECTION	7. HANDLING AND	STORAGE	

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding
		and bonding, or inert atmospheres.
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling	:	Do not breathe dust.
		Do not swallow.
		Do not get in eyes.
		Avoid prolonged or repeated contact with skin.
		Wash skin thoroughly after handling.
		Handle in accordance with good industrial hygiene and safety
		practice, based on the results of the workplace exposure
		assessment
		Minimize dust generation and accumulation.
		Keep container closed when not in use.
		Keep away from heat and sources of ignition.
		Take precautionary measures against static discharges.
		Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage	:	Keep in properly labeled containers.
_		Store locked up.
		Store in accordance with the particular national regulations.
Materials to avoid	:	Do not store with the following product types:
		Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

inert or nuisance dust	50 Million particles per cubic foot Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	15 mg/m³ Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	5 mg/m³ Value type (Form of exposure): TWA (respirable fraction) Basis: OSHA Z-3



according to the OSHA Hazard Communication Standard

Sitagliptin / Ipragliflozin L-Proline Formulation

rsion	Revision Date: 09/30/2023	SDS Number: 3121447-00013		t issue: 04/04/2023 t issue: 08/28/2018					
		15 Million particles per cubic foot Value type (Form of exposure): TWA (respirable fraction) Basis: OSHA Z-3							
Dust, nuisance dust and par- ticulates			10 mg/m³ Value type (Form of exposure): PEL (Total dust) Basis: CAL PEL						
		5 mg/m³ Value type (Fo Basis: CAL PE		: PEL (respirable du	st fraction)				
Comp	ponents	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis				
Cellul	ose	9004-34-6	TWA	10 mg/m ³	ACGIH				
			TWA (Res- pirable)	5 mg/m ³	NIOSH RE				
			TWA (total)	10 mg/m ³	NIOSH RE				
			TWA (total dust)	15 mg/m ³	OSHA Z-1				
			TWA (respir- able fraction)	5 mg/m³	OSHA Z-1				
	iflozin L-proline	951382-34-6	TWA	0.4 mg/m3 (OEB 2)	Internal				
Sitagl	iptin	654671-77-9	TWA	0.5 mg/m3 (OEB 2)	Internal				
Magn	esium stearate	557-04-0	TWA (Inhal- able particu- late matter)	10 mg/m ³	ACGIH				
			TWA (Res- pirable par- ticulate mat- ter)	3 mg/m ³	ACGIH				
Engir	neering measures	compound. All engineerir design and oj	ng controls shoul	trols to minimize exp d be implemented by dance with GMP prin d the environment.	/ facility				
Perso	onal protective equipm	ent							
Respi	iratory protection	maintain vapo concentration unknown, app Follow OSHA use NIOSH/M by air purifyin hazardous ch	or exposures bel ls are above reco propriate respira respirator regul ISHA approved g respirators ag- lemical is limited	ntilation is recommer ow recommended lin ommended limits or a tory protection should ations (29 CFR 1910 respirators. Protection ainst exposure to any . Use a positive pres	nits. Where are d be worn. 0.134) and n provided / sure air				

release, exposure levels are unknown, or any other



Version 3.1	Revision Date: 09/30/2023	SDS Number: 3121447-00013	Date of last issue: 04/04/2023 Date of first issue: 08/28/2018				
	protection aterial	circumstance adequate prot					
Eye p	protection	 Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditio mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, o aerosols. 					
	and body protection ene measures	: If exposure to eye flushing sy working place. When using de Wash contami The effective of engineering co appropriate de industrial hygi	or laboratory coat. chemical is likely during typical use, provide ystems and safety showers close to the o not eat, drink or smoke. nated clothing before re-use. operation of a facility should include review of ontrols, proper personal protective equipment, egowning and decontamination procedures, ene monitoring, medical surveillance and the strative controls.				

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available

SAFETY DATA SHEET according to the OSHA Hazard Communication Standard



Sitagliptin / Ipragliflozin L-Proline Formulation

Version Revision Date: 3.1 09/30/2023	SDS Number:Date of last issue: 04/04/20233121447-00013Date of first issue: 08/28/2018
Vapor pressure	: No data available
Relative vapor density	: No data available
Relative density	: No data available
Density	: No data available
Solubility(ies) Water solubility	: No data available
Partition coefficient: n- octanol/water	: No data available
Autoignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity Viscosity, kinematic	: No data available
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available
Particle size	: No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	:	Not classified as a reactivity hazard. Stable under normal conditions. May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials Hazardous decomposition products		Oxidizing agents No hazardous decomposition products are known.
producto		

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

according to the OSHA Hazard Communication Standard



ersion I	Revision Date: 09/30/2023	SDS Num 3121447-		Date of last issue: 04/04/2023 Date of first issue: 08/28/2018
Acute	e toxicity			
Not cl	assified based on av	ailable informa	ation.	
Produ	uct:			
Acute	oral toxicity			imate: > 5,000 mg/kg ion method
Comp	oonents:			
Cellu	lose:			
Acute	oral toxicity	: LD50	(Rat): > 5,0	000 mg/kg
Acute	inhalation toxicity	Expos	(Rat): > 5.8 sure time: 4 atmosphere	h
Acute	dermal toxicity	: LD50	(Rabbit): >	2,000 mg/kg
lprag	liflozin L-proline:			
	oral toxicity	: LD50	(Rat): < 1,0	000 mg/kg
		LDLo	(Monkey):	>= 1,000 mg/kg
Sitag	liptin:			
Acute	oral toxicity	: LD50	(Rat): > 3,0	000 mg/kg
		LD50	(Mouse): 3	,000 mg/kg
Magn	esium stearate:			
Acute	oral toxicity	Metho Asses icity	sment: The	000 mg/kg Test Guideline 423 e substance or mixture has no acute oral to on data from similar materials
Acute	dermal toxicity			2,000 mg/kg on data from similar materials
Skin	corrosion/irritation			
Not cl	assified based on av	ailable informa	ation.	
<u>Comp</u>	oonents:			
Sitag	liptin:			
Speci		: Rabbi		
Metho Resul		: Draize : No sk	e Test in irritation	
Magn	esium stearate:			
Speci		: Rabbi	t	

according to the OSHA Hazard Communication Standard



ersion 1	Revision Date: 09/30/2023	SDS Number: 3121447-00013	Date of last issue: 04/04/2023 Date of first issue: 08/28/2018
Result Remarks		: No skin irritat : Based on dat	tion ta from similar materials
Serio	us eye damage/eye	irritation	
	es serious eye irritatio		
<u>Com</u>	oonents:		
	liflozin L-proline:		
Speci Resu		: Rabbit : Mild eye irrita	ation
Resu	i.	. Wind Cyc infic	
-	liptin:		
Speci Resu		: Rabbit : Irritating to ey	100
Metho		: Draize Test	yes.
Moan	acium staarata		
Speci	esium stearate:	: Rabbit	
Resu		: No eye irritati	ion
Rema	arks		ta from similar materials
Resp	iratory or skin sensi	itization	
-	iratory or skin sensi sensitization	itization	
Skin	-		
Skin Not c	sensitization	ailable information.	
Skin Not c Resp	sensitization lassified based on ava	ailable information.	
Skin Not c Resp Not c	sensitization lassified based on ava iratory sensitization	ailable information.	
Skin Not c Resp Not c <u>Com</u>	sensitization lassified based on ava iratory sensitization lassified based on ava	ailable information.	
Skin Not c Resp Not c <u>Com</u> Iprag	sensitization lassified based on ava iratory sensitization lassified based on ava ponents: liflozin L-proline: Type	ailable information. ailable information. : Maximization	Test
Skin Not c Resp Not c Com Iprag Test Route	sensitization lassified based on avainatory sensitization lassified based on avainator conents: liflozin L-proline: Type es of exposure	ailable information. ailable information. : Maximization : Dermal	
Skin Not c Resp Not c <u>Com</u> Iprag	sensitization lassified based on avainatory sensitization lassified based on avainator conents: liflozin L-proline: Type es of exposure	ailable information. ailable information. : Maximization	
Skin Not c Resp Not c Com Iprag Test Route Resu	sensitization lassified based on avaination lassified based on avaination lassified based on avaination <u>ponents:</u> liflozin L-proline: Type es of exposure lt liptin:	ailable information. ailable information. : Maximization : Dermal : Not a skin se	nsitizer.
Skin Not c Resp Not c Com Iprag Test Route Resu Sitag Test	sensitization lassified based on avainatory sensitization lassified based on avaination lassified based on avaination lassified based on avaination lassified based on avaination lassified based on avaination listin: Type	ailable information. ailable information. : Maximization : Dermal : Not a skin se : Local lymph i	
Skin Not c Resp Not c Com Iprag Test Route Resu Sitag Test Spec	sensitization lassified based on avainatory sensitization lassified based on avaination lassified based on avaination lassifie	ailable information. ailable information. : Maximization : Dermal : Not a skin se : Local lymph i : Mouse	nsitizer. node assay (LLNA)
Skin Not c Resp Not c Com Iprag Test Route Resu Sitag Test	sensitization lassified based on avainatory sensitization lassified based on avainator lassified based on avainator ponents: liflozin L-proline: Type les of exposure lt liptin: Type les	ailable information. ailable information. : Maximization : Dermal : Not a skin se : Local lymph i	nsitizer. node assay (LLNA) Guideline 429
Skin Not c Resp Not c Com Iprag Test Route Resu Sitag Test Speci Metho Resu	sensitization lassified based on avaination lassified based on ava	ailable information. ailable information. : Maximization : Dermal : Not a skin se : Local lymph i : Mouse : OECD Test 0	nsitizer. node assay (LLNA) Guideline 429
Skin Not c Resp Not c Com Iprag Test Route Resu Sitag Test Speci Metho Resu	sensitization lassified based on availassified based on availassified based on availassified based on availassified based on availaborents: liflozin L-proline: Type es of exposure lt liptin: Type les od lt	ailable information. ailable information. : Maximization : Dermal : Not a skin se : Local lymph i : Mouse : OECD Test 0	nsitizer. node assay (LLNA) Guideline 429 nsitizer.
Skin Not c Resp Not c Com Iprag Test Route Resu Sitag Test Speci Metho Resu Magn Test	sensitization lassified based on availassified based on availassifie	ailable information. ailable information. : Maximization : Dermal : Not a skin se : Local lymph i : Mouse : OECD Test C : Not a skin se : Not a skin se	nsitizer. node assay (LLNA) Guideline 429 nsitizer.
Skin Not c Resp Not c Com Iprag Test Route Resu Sitag Test Speci Metho Resu Magn Test	sensitization lassified based on availassified based on availassifie	ailable information. ailable information. : Maximization : Dermal : Not a skin se : Local lymph i : Mouse : OECD Test C : Not a skin se : Not a skin se : Skin contact : Guinea pig	node assay (LLNA) Guideline 429 nsitizer.
Skin Not c Resp Not c Com Iprag Test Route Resu Sitag Test Speci Metho Resu Magn Test	sensitization lassified based on availassified based on availassifie	ailable information. ailable information. : Maximization : Dermal : Not a skin se : Local lymph i : Mouse : OECD Test C : Not a skin se : Not a skin se	node assay (LLNA) Guideline 429 nsitizer.

according to the OSHA Hazard Communication Standard



Ver 3.1	sion	Revision Date: 09/30/2023		DS Number: 21447-00013	Date of last issue: 04/04/2023 Date of first issue: 08/28/2018
		cell mutagenicity assified based on availa	able	information.	
	Comp	onents:			
	Cellulo	ose:			
	Genoto	oxicity in vitro	:	Test Type: Bacter Result: negative	rial reverse mutation assay (AMES)
				Test Type: In vitro Result: negative	o mammalian cell gene mutation test
	Genoto	oxicity in vivo	:	Test Type: Mamm cytogenetic assay Species: Mouse Application Route Result: negative	
	Ipragli	flozin L-proline:			
		oxicity in vitro	:	Test Type: Bacter Result: negative	rial reverse mutation assay (AMES)
					nosomal aberration nese hamster lung cells
	Genoto	oxicity in vivo	:	Test Type: Micror Species: Rat Cell type: Bone m Result: negative	
	Sitagli	ptin:			
	-	oxicity in vitro	:	Test Type: Ames Result: negative	test
					nosome aberration test in vitro nese hamster ovary cells
				Test Type: DNA c thesis in mammal Test system: rat h Result: negative	
	Genoto	oxicity in vivo	:	Test Type: Micror Species: Mouse Application Route Result: negative	
	Magne	esium stearate:			
	-	oxicity in vitro	:	Test Type: In vitro Result: negative	o mammalian cell gene mutation test

SAFETY DATA SHEET according to the OSHA Hazard Communication Standard



ersion	Revision Date: 09/30/2023	SDS Number: 3121447-00013	Date of last issue: 04/04/2023 Date of first issue: 08/28/2018
		Remarks: Base	d on data from similar materials
		Method: OECD	omosome aberration test in vitro Test Guideline 473
		Result: negative Remarks: Base	e d on data from similar materials
		Result: negative	terial reverse mutation assay (AMES) e d on data from similar materials
		Remarks. Dase	
	nogenicity		
Not cl	assified based on av	ailable information.	
Comp	oonents:		
Cellu	lose:		
Speci	es	: Rat	
	cation Route	: Ingestion	
	sure time	: 72 weeks	
Resul	t	: negative	
Iprag	liflozin L-proline:		
Speci	-	: Mouse	
	cation Route	: Oral	
	sure time	: 2 years	
NOAE		: 500 mg/kg bod	v weight
Resul	t	: negative	
Speci	es	: Rat, male	
	cation Route	: Oral	
	sure time	: 2 years	
NÓAE	EL	: 12.5 mg/kg boo	ly weight
LOAE	E	: 40 mg/kg body	weight
Resul		: positive	
Rema	arks	: The mechanish	n or mode of action is not relevant in humans
Speci	es	: Rat, female	
	cation Route	: Oral	
	sure time	: 2 years	
LOAE		: > 125 mg/kg bo	ody weight
Resul		: positive	
Rema	Irks	: The mechanish	n or mode of action is not relevant in humans
Sitag	liptin:		
Speci	es	: Mouse	
Applic	cation Route	: Oral	
	sure time	: 2 Years	
Resul		: negative	
Speci		: Rat	
Annlia	cation Route	: oral (drinking w	ater)



Version 3.1	Revisio 09/30/2	on Date: 2023		0S Number: 21447-00013	Date of last issue: 04/04/2023 Date of first issue: 08/28/2018
Resu	et Organs		:	2 Years positive Liver Significant toxicity	v observed in testing
Carci ment		- Assess-	:	Weight of evidenc	e does not support classification as a car-
IARC	;				t at levels greater than or equal to 0.1% is onfirmed human carcinogen by IARC.
OSH/	A			this product prese regulated carcinog	nt at levels greater than or equal to 0.1% is lens.
NTP					t at levels greater than or equal to 0.1% is carcinogen by NTP.
Susp	oductive ected of d ponents:	toxicity amaging the u	nbo	rn child.	
	ilose: ts on fertili	ty	:	Test Type: One-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study : Ingestion
Effect	ts on fetal	development	:	Test Type: Fertilit Species: Rat Application Route Result: negative	y/early embryonic development : Ingestion
• •	Jliflozin L- ts on fetal	proline: development	:		
				Species: Rat Application Route Developmental To	eneration reproduction toxicity study : Oral oxicity: NOAEL: 100 mg/kg body weight postnatal development.
Repro	oductive to	oxicity - As-	:	Some evidence o	f adverse effects on development, based on



according to the OSHA Hazard Communication Standard

Sitagliptin / Ipragliflozin L-Proline Formulation

ersion .1	Revision Date: 09/30/2023		OS Number: 21447-00013	Date of last issue: 04/04/2023 Date of first issue: 08/28/2018			
sessment			animal experiments.				
Sitag	liptin:						
Effects on fertility			Test Type: Fertility/early embryonic development Species: Rat Application Route: Oral Fertility: NOAEL Parent: 1,000 mg/kg body weight Result: Animal testing did not show any effects on fertility				
Effects on fetal development		:	Test Type: Embryo-fetal development Species: Rat Application Route: Oral Teratogenicity: LOAEL: 250 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.				
			Test Type: Embryo-fetal development Species: Rabbit Teratogenicity: NOAEL: 125 mg/kg body weight Result: No teratogenic effects.				
Magr	nesium stearate:						
Effects on fertility			Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422 Result: negative Remarks: Based on data from similar materials				
Effec	ts on fetal development	:	Species: Rat Application Route Result: negative	vo-fetal development :: Ingestion on data from similar materials			
STO	Γ-single exposure						
	lassified based on availa	able	information.				
STOT-repeated exposure							

STOT-repeated exposure

May cause damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Components:

Ipragliflozin L-proline:	
--------------------------	--

Target Organs	:	Kidney, Liver
Assessment	:	May cause damage to organs through prolonged or repeated
		exposure.

according to the OSHA Hazard Communication Standard



Version 3.1	Revision Date: 09/30/2023	SDS Number: 3121447-00013	Date of last issue: 04/04/2023 Date of first issue: 08/28/2018
Repe	ated dose toxicity		
<u>Com</u>	oonents:		
Cellu	lose:		
Speci	es	: Rat	
NOA		: >= 9,000 mg/kg	
	cation Route	: Ingestion	
	sure time	: 90 Days	
Iprag	liflozin L-proline:		
Speci	es	: Rat	
NOA		: 0.1 mg/kg	
Applie	cation Route	: Oral	
	sure time	: 26 weeks	
Targe	et Organs	: Kidney, Liver, G	astrointestinal tract
Speci		: Monkey, male a	nd female
NOAE		: 1 - 10 mg/kg	
LOAE		: 10 - 300 mg/kg	
	cation Route sure time	: Oral : 52 weeks	
	et Organs	: Kidney, Liver	
raige	a organo		
-	liptin:		
Speci		: Mouse	
NOA		: 500 mg/kg	
LOAE		: 1,000 mg/kg	
	cation Route sure time	: Oral	
	et Organs	: > 2 y : Kidney	
-	-	·	
Speci		: Rat	
NOA		: 500 mg/kg	
LOAE		: 1,000 mg/kg	
	cation Route sure time	: Oral : 14 Weeks	
	et Organs	: Liver, Kidney, H	eart Teeth
-	-	-	
Speci		: Dog	
NOAE		: 10 mg/kg	
LOAE		: 50 mg/kg	
	cation Route	: Oral : 53 Weeks	
	sure time et Organs	: Central nervous	system
Symp		: Loss of balance	
Rema			or mode of action may not be relevant in
		humans.	
Speci	es	: Dog	
NOA	EL	: 2 mg/kg	
LOAE		: 10 mg/kg	
Appli	cation Route	: Oral	





Versio 3.1	'n	Revision Date: 09/30/2023	-	0S Number: 21447-00013	Date of last issue: 04/04/2023 Date of first issue: 08/28/2018
Ta Sy				Loss of balance	Central nervous system r mode of action may not be relevant in
N Aj Ex		tion Route re time		Monkey 100 mg/kg Oral 14 Weeks No significant adv	erse effects were reported
М	lagnes	sium stearate:			
SI N(AI E)	pecies OAEL pplicat	tion Route re time		Rat > 100 mg/kg Ingestion 90 Days Based on data fro	m similar materials
	•	ion toxicity sified based on availa	ble	information.	
		ence with human exp			
	-	nents:			
		lozin L-proline:			
-	kin coi	-	:	Target Organs: Sl	xin
	ngestio		:	Symptoms: Eczer Target Organs: Ki Symptoms: consti	na dney
Si	itaglip	otin:			
	halatio		:	Symptoms: upper Headache	respiratory tract infection, pharyngitis,
In	ngestio	'n	:		respiratory tract infection, nasopharyngitis, a, Abdominal pain, Diarrhea
SECTI	ION 12	2. ECOLOGICAL INFO	DRN	IATION	
E	cotox	icity			
<u>C</u>	ompo	nents:			
	ellulo: oxicity	se: to fish	:	Exposure time: 48	pes (Japanese medaka)): > 100 mg/l 3 h on data from similar materials
lp	oraglif	lozin L-proline:			
		icology Assessment quatic toxicity	:	Toxic effects canr	not be excluded

Acute aquatic toxicity	:	Toxic effects cannot be excluded
------------------------	---	----------------------------------

SAFETY DATA SHEET according to the OSHA Hazard Communication Standard



Vers 3.1	sion	Revision Date: 09/30/2023		9S Number: 21447-00013	Date of last issue: 04/04/2023 Date of first issue: 08/28/2018
	Chronic	aquatic toxicity	:	Toxic effects cann	ot be excluded
	Sitagliņ Toxicity		:	LC50 (Pimephales Exposure time: 96 Method: OECD Te	
		to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
	Toxicity plants	v to algae/aquatic	:	EC50 (Pseudokiro mg/l Exposure time: 96 Method: OECD Te	
				NOEC (Pseudokir mg/l Exposure time: 96 Method: OECD Te	
	Toxicity icity)	to fish (Chronic tox-	:	NOEC (Pimephale Exposure time: 33 Method: OECD Te	
		to daphnia and other invertebrates (Chron- ty)	:	NOEC (Daphnia n Exposure time: 21 Method: OECD Te	
	Toxicity	to microorganisms	:	EC50: > 150 mg/l Exposure time: 3 l Test Type: Respire Method: OECD Te	ation inhibition
				NOEC: 150 mg/l Exposure time: 3 l Test Type: Respire	
		sium stearate:			
	Toxicity		:	Exposure time: 48 Method: DIN 3841	
		to daphnia and other invertebrates	:	Exposure time: 47 Test substance: W Method: Directive	/ater Accommodated Fraction 67/548/EEC, Annex V, C.2. on data from similar materials



ersion .1	Revision Date: 09/30/2023	-	OS Number: 21447-00013	Date of last issue: 04/04/2023 Date of first issue: 08/28/2018
Toxici plants	ity to algae/aquatic	:	mg/l Exposure time: 7 Test substance: Method: OECD T Remarks: Based No toxicity at the NOELR (Pseudo mg/l Exposure time: 7 Test substance: Method: OECD T	Water Accommodated Fraction Fest Guideline 201 I on data from similar materials I limit of solubility. Ikirchneriella subcapitata (green algae)): > 1
Toxic	ity to microorganisms	:	Exposure time: 1 Test substance:	onas putida): > 100 mg/l 6 h Water Accommodated Fraction on data from similar materials
Persi	stence and degradab	ility		
Comp	oonents:			
Cellu	lose:			
Biode	gradability	:	Result: Readily b	biodegradable.
-	liptin: gradability	:	Result: not rapid Biodegradation: Exposure time: 2 Method: OECD	39.7 %
Stabil	ity in water	:	Hydrolysis: 50 % Method: OECD 1	o(401 d) Fest Guideline 111
-	esium stearate: gradability	:	Result: Not biode Remarks: Based	egradable on data from similar materials
Bioac	cumulative potential			
Comp	oonents:			
Partiti	liptin: on coefficient: n- ol/water	:	log Pow: -0.03	
Partiti	esium stearate: on coefficient: n- ol/water	:	log Pow: > 4	

according to the OSHA Hazard Communication Standard



Sitagliptin / Ipragliflozin L-Proline Formulation

Versi 3.1	ion	Revision Date: 09/30/2023		DS Number: 21447-00013	Date of last issue: 04/04/2023 Date of first issue: 08/28/2018
I	Mobility	y in soil			
9	Compo	nents:			
I		otin: tion among environ- compartments	:	log Koc: 4.37	
		dverse effects available			
SEC	TION 13	3. DISPOSAL CONSI	DEF	RATIONS	
I	Dispos	al methods			
	-	rom residues	:		ordance with local regulations.
(Contam	inated packaging	:	Empty containers handling site for r	waste into sewer. should be taken to an approved waste ecycling or disposal. pecified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust

SAFETY DATA SHEET according to the OSHA Hazard Communication Standard



Sitagliptin / Ipragliflozin L-Proline Formulation

Version 3.1	Revision Date: 09/30/2023		DS Number: 21447-00013	Date of last issue: 04/04/2023 Date of first issue: 08/28/2018
				ricity gan toxicity (single or repeated exposure) age or eye irritation
SAR	A 313	:	known CAS num	es not contain any chemical components with bers that exceed the threshold (De Minimis) established by SARA Title III, Section 313.
US S	tate Regulations			
Penn	sylvania Right To Kr	now		
	Cellulose Ipragliflozin L-pro Sitagliptin Starch, carboxyn Hydroxypropyl ce Magnesium stea	nethyl ellulos	ether, sodium salt e	9004-34-6 951382-34-6 654671-77-9 9063-38-1 9004-64-2 557-04-0
Califo	ornia Permissible Ex	posu	re Limits for Cher	nical Contaminants
	Cellulose Magnesium stea	rate		9004-34-6 557-04-0
The i	ngredients of this pr	oduct	are reported in t	he following inventories:
AICS		:	not determined	
DSL		:	not determined	
IECS	С	:	not determined	


SECTION 16. OTHER INFORMATION

Further information



according to the OSHA Hazard Communication Standard

Sitagliptin / Ipragliflozin L-Proline Formulation



AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Pre-



Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.1	09/30/2023	3121447-00013	Date of first issue: 08/28/2018

vention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Material Safety Data Sheet		eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/

09/30/2023

:

Revision Date

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8